

Santen Announces the Construction of China Second Plant

January 6, 2020, Osaka, Japan—Santen Pharmaceutical Co., Ltd. (hereinafter, “Santen”) announced that it has decided the construction of a second plant for our Chinese subsidiary “Santen Pharmaceutical (China) Co., Ltd.” in order to meet growing demand for products in China.

Our China business, which has been growing rapidly in recent years, accounts for approximately 60% of our sales in China and the Asian region. Since fiscal 2019, we have operated our business in China as a “China Business” for a single country. In China, despite continued aging of the population, high economic growth is expected to continue, and the ophthalmology market is expected to expand further as a result of the increase in the number of patients and improvements in the healthcare system.

Shigeo Taniuchi, President and COO at Santen said, “We have decided to establish a new product supply plant in order to consolidate the growth of our business in China, which is Santen's growth driver and the largest overseas business, over the long term. The Company will further strengthen its competitiveness by ensuring overwhelming supply and quality, and continue to contribute to the development of ophthalmology in China”

The timing and details of the construction of the second plant will be determined in the future.

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (www.santen.com).

Santen Forward-looking Statements

Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact

Corporate Communications Group, Santen Pharmaceutical Co., Ltd.

+81-6-4802-9360, ir@santen.com